Schwager SM - Search Results

1

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Gangat N, et al. Among authors: schwager sm. Cancer. 2006 Jun 1;106(11):2406-11. doi: 10.1002/cncr.21891. Cancer. 2006. PMID: 16628652 Free article.

2

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Tefferi A, et al. Among authors: schwager sm. Br J Haematol. 2005 Oct;131(2):166-71. doi: 10.1111/j.1365-2141.2005.05743.x. Br J Haematol. 2005. PMID: 16197445 Free article.

3

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.

Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A. Wolanskyj AP, et al. Among authors: schwager sm. Br J Haematol. 2005 Oct;131(2):208-13. doi: 10.1111/j.1365-2141.2005.05764.x. Br J Haematol. 2005. PMID: 16197451 Free article.

4

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. Tefferi A, et al. Among authors: schwager sm. Br J Haematol. 2005 Nov;131(3):320-8. doi: 10.1111/j.1365-2141.2005.05776.x. Br J Haematol. 2005. PMID: 16225651 Free article.

5

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG. Tefferi A, et al. Among authors: schwager sm. Cancer. 2006 Feb 1;106(3):631-5. doi: 10.1002/cncr.21645. Cancer. 2006. PMID: 16369984 Free article.

6

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.

Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Dingli D, et al. Among authors: schwager sm. Cancer. 2006 Feb 1;106(3):623-30. doi: 10.1002/cncr.21644. Cancer. 2006. PMID: 16369987 Free article.

7

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Wolanskyj AP, et al. Among authors: schwager sm. Mayo Clin Proc. 2006 Feb;81(2):159-66. doi: 10.4065/81.2.159. Mayo Clin Proc. 2006. PMID: 16471068

8

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Dingli D, et al. Among authors: schwager sm. Cancer. 2006 May 1;106(9):1985-9. doi: 10.1002/cncr.21868. Cancer. 2006. PMID: 16568439 Free article.

9

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Mesa RA, et al. Cancer. 2006 Jul 15;107(2):361-70. doi: 10.1002/cncr.22021. Cancer. 2006. PMID: 16770787 Free article.

10

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, Tefferi A. Gangat N, et al. Leukemia. 2007 Feb;21(2):270-6. doi: 10.1038/sj.leu.2404500. Epub 2006 Dec 14. Leukemia. 2007. PMID: 17170720

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters